Glucosamine binding to proteins in plasma and synovial fluid and blood cell/plasma partitioning in mouse and man in vitro

Drug Metabolism and Drug Interactions

Volumn 24, Issue 2-4, 2009, Pages 211-227

  Persiani, Stefano ^a   Matthews, Anne ^b   Larger, Patrice ^a   Hall, Michael ^b   Rotini, Roberto ^c   Trisolino, Giovanni ^c   Antonioli, Diego ^c   Zaccarelli, Lorenzo ^c   Rovati, Lucio C ^a  

^a Rotta Research Laboratorium   (Italy)

^b HUNTINGDON LIFE SCIENCES   (United Kingdom)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Blood cell plasma partitioning; Crystalline glucosamine sulphate; Drug drug interactions; Plasma protein binding; Synovial fluid

Indexed keywords

GLUCOSAMINE; GLUCOSAMINE SULFATE;

ARTICLE; BLOOD CELL; HUMAN; IN VITRO STUDY; KNEE OSTEOARTHRITIS; MOUSE; NONHUMAN; PLASMA; PLASMA CLEARANCE; PROTEIN BINDING; RADIOACTIVITY; RADIOCHEMISTRY; SYNOVIAL FLUID;

EID: 77950604463     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2009.24.2-4.211     Document Type: Article

References (16)

1. Altman RD, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 28: 1039-1049.
2. McAlindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469-1475. (Pubitemid 30151826)
3. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. A comprehensive meta-analysis. Arch Int Med 2003; 163: 1514-1522.
4. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G. Glucosamine therapy for treating osteoarthritis. Cochrane Database System Rev 2005; (2): CD002946.
5. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-256. (Pubitemid 32120855)
6. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-2123. (Pubitemid 35168220)
7. Pavelka K, Bruyere O, Rovati LC, Olejárova M, Giacovelli G, Reginster JY. Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis Cartilage 2003; 11: 730-737. (Pubitemid 37184491)
8. Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, Giacovelli G, Reginster JY. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 2004; 11: 138-143. (Pubitemid 40353230)
9. Herrero-Beaumont G, Ivorra JAR, Trabado MDC, Blanco FJ, Benito P, Martìn-Mola E, Paulino J, Marenci JL, Porto A, Laffon A, Araùjo D, Figueroa M, Branco J. Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms against placebo and acetaminophen: the Glucosamine Unum In Die Efficacy (GUIDE) trial. Arthritis Rheum 2007; 56: 555-567.
10. Trainor G. The importance of plasma protein binding in drug discovery. Expert Opin Drug Discov 2007; 2: 51-64. (Pubitemid 47078697)
11. Benet L, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121. (Pubitemid 34271114)
12. Persiani S, Larger P. Strategies to assess the drug interaction potential in translational medicine. Expert Opin Drug Metab Toxicol 2006; 2: 675-686. (Pubitemid 46118316)
13. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005; 13: 1041-1049. (Pubitemid 41672501)
14. Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D, Antonioli D, Roda A. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulfate at therapeutic dose. Osteoarthritis Cartilage 2007; 15: 764-772. (Pubitemid 46888164)
15. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. Arzneim Forsch Drug Res 2001; 51: 699-725. (Pubitemid 32889393)
16. Altman R. Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol 2009; 2: 359-371.